Kenichiro Uemura1, Yoshiaki Murakami2, Sohei Satoi3, Masayuki Sho4, Fuyuhiko Motoi5, Manabu Kawai6, Ippei Matsumoto7, Goro Honda8, Masanao Kurata8, Hiroaki Yanagimoto3, Satoshi Nishiwada4, Takumi Fukumoto7, Michiakil Unno5, Hiroki Yamaue6. 1. Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. umk@hiroshima-u.ac.jp. 2. Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. 3. Department of Surgery, Kansai Medical University, Osaka, Japan. 4. Department of Surgery, Nara Medical University, Nara, Japan. 5. Division of Gastroenterological Surgery, Department of Surgery, Tohoku University, Sendai, Japan. 6. Second Department of Surgery, Wakayama Medical University, Wakayama, Japan. 7. Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan. 8. Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Abstract
BACKGROUND: This study aimed to evaluate the impact of preoperative biliary drainage (PBD) on the long-term survival of patients with pancreatic ductal adenocarcinoma (PDAC) who underwent pancreaticoduodenectomy (PD). METHODS: A multicenter observational study was performed using a common database of patients with resected PDAC from seven high-volume surgical institutions in Japan. RESULTS: Of 932 patients who underwent PD for PDAC, 573 (62 %) underwent PBD, including 407 (44 %) who underwent endoscopic biliary drainage (EBD) and 166 (18 %) who underwent percutaneous transhepatic biliary drainage (PTBD). The patients who did not undergo PBD and those who underwent EBD had a significantly better overall survival than those who underwent PTBD, with median survival times of 25.7 months (P < 0.001), 22.3 months (P = 0.001), and 16.7 months, respectively. Multivariate analysis showed that seven clinicopathologic factors, including the use of PTBD but not EBD, were independently associated with poorer overall survival. Furthermore, patients who underwent PTBD more frequently experienced peritoneal recurrence (23 %) than those who underwent EBD (10 %; P < 0.001) and those who did not undergo PBD (11 %; P = 0.001). Multivariate analysis demonstrated that the independent risk factors for peritoneal recurrence included surgical margin status (P < 0.001) and use of PTBD (P = 0.004). CONCLUSIONS: Use of PTBD, but not EBD, was associated with a poorer prognosis, with an increased rate of peritoneal recurrence among patients who underwent PD for PDAC.
BACKGROUND: This study aimed to evaluate the impact of preoperative biliary drainage (PBD) on the long-term survival of patients with pancreatic ductal adenocarcinoma (PDAC) who underwent pancreaticoduodenectomy (PD). METHODS: A multicenter observational study was performed using a common database of patients with resected PDAC from seven high-volume surgical institutions in Japan. RESULTS: Of 932 patients who underwent PD for PDAC, 573 (62 %) underwent PBD, including 407 (44 %) who underwent endoscopic biliary drainage (EBD) and 166 (18 %) who underwent percutaneous transhepatic biliary drainage (PTBD). The patients who did not undergo PBD and those who underwent EBD had a significantly better overall survival than those who underwent PTBD, with median survival times of 25.7 months (P < 0.001), 22.3 months (P = 0.001), and 16.7 months, respectively. Multivariate analysis showed that seven clinicopathologic factors, including the use of PTBD but not EBD, were independently associated with poorer overall survival. Furthermore, patients who underwent PTBD more frequently experienced peritoneal recurrence (23 %) than those who underwent EBD (10 %; P < 0.001) and those who did not undergo PBD (11 %; P = 0.001). Multivariate analysis demonstrated that the independent risk factors for peritoneal recurrence included surgical margin status (P < 0.001) and use of PTBD (P = 0.004). CONCLUSIONS: Use of PTBD, but not EBD, was associated with a poorer prognosis, with an increased rate of peritoneal recurrence among patients who underwent PD for PDAC.
Authors: Ahmer Hameed; Tony Pang; Judy Chiou; Henry Pleass; Vincent Lam; Michael Hollands; Emma Johnston; Arthur Richardson; Lawrence Yuen Journal: HPB (Oxford) Date: 2016-04-04 Impact factor: 3.647
Authors: D J Kagedan; J D Mosko; M E Dixon; P J Karanicolas; A C Wei; N Goyert; Q Li; N Mittmann; N G Coburn Journal: Curr Oncol Date: 2018-10-31 Impact factor: 3.677